Vital Therapies price target raised to $35 from $20 at Canaccord Canaccord raised its price target on Vital Therapies to $35 from $20 based on the probability of the success of its Alcohol Induced Liver Disease drug and its substantial market opportunity. Canaccord maintains its Buy rating on Vital Therapies.
Vital Therapies downgraded to Neutral from Outperform at Credit Suisse Credit Suisse downgraded Vital Therapies to Neutral following the announcement VTI 208 missed its primary endpoint but sees the potential for approval in a lower MELD score cohort in the 2020 time frame. The firm lowered its price target on shares to $9 from $25.
Vital Therapies volatility elevated into topline clinical trial results Vital Therapies August call option implied volatility is at 188, September is at 234; compared to its 52-week range of 70 to 423, suggesting large price movement into expected release of topline results of the VTI-208 clinical trial.